Search Results

There are 7786100 results for: content related to: Use of intrapleural bortezomib in myelomatous pleural effusion

  1. Bortezomib for the treatment of multiple myeloma

    Intervention Review

    The Cochrane Library

    Kathleen Scott, Patrick J Hayden, Andrea Will, Keith Wheatley and Imelda Coyne

    Published Online : 20 APR 2016, DOI: 10.1002/14651858.CD010816.pub2

  2. Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells

    Journal of Periodontal Research

    Volume 50, Issue 2, April 2015, Pages: 248–255, J. Kitagaki, S. Miyauchi, C. J Xie, M. Yamashita, S. Yamada, M. Kitamura and S. Murakami

    Version of Record online : 20 JUN 2014, DOI: 10.1111/jre.12202

  3. You have free access to this content
    Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically

    BJU International

    Volume 109, Issue 8, April 2012, Pages: 1258–1268, Akinori Sato, Takako Asano, Keiichi Ito, Makoto Sumitomo and Tomohiko Asano

    Version of Record online : 2 SEP 2011, DOI: 10.1111/j.1464-410X.2011.10533.x

  4. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage

    Molecular Carcinogenesis

    Volume 52, Issue 2, February 2013, Pages: 118–133, Daniel R. Premkumar, Esther P. Jane, Naomi R. Agostino, Joseph D. DiDomenico and Ian F. Pollack

    Version of Record online : 15 NOV 2011, DOI: 10.1002/mc.21835

  5. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma

    British Journal of Haematology

    Volume 168, Issue 1, January 2015, Pages: 55–62, Michelle Furtado, Rod Johnson, Anton Kruger, Deborah Turner and Simon Rule

    Version of Record online : 22 AUG 2014, DOI: 10.1111/bjh.13101

  6. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines

    International Journal of Laboratory Hematology

    Volume 34, Issue 3, June 2012, Pages: 237–247, B. ZHENG, R. ZHOU, Y. GONG, X. YANG and Q. SHAN

    Version of Record online : 7 DEC 2011, DOI: 10.1111/j.1751-553X.2011.01384.x

  7. Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy

    Glia

    Volume 58, Issue 16, December 2010, Pages: 1961–1976, Yoon Kyung Shin, So Young Jang, Hyun Kyoung Lee, Junyang Jung, Duk Joon Suh, Su-Yeong Seo and Hwan Tae Park

    Version of Record online : 9 SEP 2010, DOI: 10.1002/glia.21065

  8. You have free access to this content
    Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study

    American Journal of Hematology

    Volume 90, Issue 4, April 2015, Pages: 314–319, María Victoria Mateos, Paul G. Richardson, Meletios A. Dimopoulos, Antonio Palumbo, Kenneth C. Anderson, Hongliang Shi, Jennifer Elliott, Edward Dow, Helgi van de Velde, Liviu Niculescu and Jesús F. San Miguel

    Version of Record online : 27 FEB 2015, DOI: 10.1002/ajh.23933

  9. You have free access to this content
    Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib

    American Journal of Hematology

    Volume 84, Issue 10, October 2009, Pages: 657–660, Raman Sood, Harry Carloss, Robert Kerr, Jose Lopez, Martin Lee, Mark Druck, Ian B. Walters and Stephen J. Noga

    Version of Record online : 30 JUL 2009, DOI: 10.1002/ajh.21517

  10. You have full text access to this Open Access content
    Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1

    Cancer Science

    Volume 100, Issue 2, February 2009, Pages: 341–348, Masaki Ri, Shinsuke Iida, Takashi Ishida, Asahi Ito, Hiroki Yano, Atsushi Inagaki, Jianmin Ding, Shigeru Kusumoto, Hirokazu Komatsu, Atae Utsunomiya and Ryuzo Ueda

    Version of Record online : 5 DEC 2008, DOI: 10.1111/j.1349-7006.2008.01038.x

  11. You have free access to this content
    A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

    British Journal of Haematology

    Volume 127, Issue 2, October-II 2004, Pages: 165–172, S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin, P. G. Richardson, R. Niesvizky, R. Alexanian, S. A. Limentani, M. Alsina, J. Adams, M. Kauffman, D.-L. Esseltine, D. P. Schenkein and K. C. Anderson

    Version of Record online : 27 SEP 2004, DOI: 10.1111/j.1365-2141.2004.05188.x

  12. You have free access to this content
    Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma

    Cancer

    Volume 113, Issue 4, 15 August 2008, Pages: 765–771, John D. Hainsworth, David R. Spigel, John Barton, Cindy Farley, Marshall Schreeder, Jeremy Hon and F. Anthony Greco

    Version of Record online : 9 JUN 2008, DOI: 10.1002/cncr.23606

  13. You have free access to this content
    The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

    British Journal of Haematology

    Volume 161, Issue 1, April 2013, Pages: 43–56, Girija Dasmahapatra, Hiral Patel, Paul Dent, Richard I. Fisher, Jonathan Friedberg and Steven Grant

    Version of Record online : 30 JAN 2013, DOI: 10.1111/bjh.12206

  14. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)

    Pediatric Blood & Cancer

    Volume 60, Issue 3, March 2013, Pages: 390–395, Jodi A. Muscal, Patrick A. Thompson, Terzah M. Horton, Ashish M. Ingle, Charlotte H. Ahern, Renee M. McGovern, Joel M. Reid, Matthew M. Ames, Igor Espinoza-Delgado, Brenda J. Weigel and Susan M. Blaney

    Version of Record online : 9 AUG 2012, DOI: 10.1002/pbc.24271

  15. You have free access to this content
    Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction

    British Journal of Haematology

    Volume 146, Issue 3, August 2009, Pages: 270–281, Tae Young Kim, Jongmin Park, Bora Oh, Hyun Jung Min, Tae-Sook Jeong, Jae Hoon Lee, Cheolwon Suh, June-Won Cheong, Hyo Jung Kim, Sung-Soo Yoon, Seung Bum Park, Dong Soon Lee and the Korean Multiple Myeloma Working Party (KMMWP)

    Version of Record online : 3 JUN 2009, DOI: 10.1111/j.1365-2141.2009.07752.x

  16. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases

    European Journal of Haematology

    Volume 80, Issue 5, May 2008, Pages: 407–418, Pavani Srimatkandada, Regina Loomis, Rocco Carbone, Srinivasan Srimatkandada and Jill Lacy

    Version of Record online : 23 JAN 2008, DOI: 10.1111/j.1600-0609.2008.01044.x

  17. You have free access to this content
    A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

    British Journal of Haematology

    Volume 160, Issue 5, March 2013, Pages: 649–659, Maria T. Petrucci, Pilar Giraldo, Paolo Corradini, Adriana Teixeira, Meletios A. Dimopoulos, Igor W. Blau, Johannes Drach, Ralf Angermund, Nathalie Allietta, Esther Broer, Vivien Mitchell and Joan Bladé

    Version of Record online : 7 JAN 2013, DOI: 10.1111/bjh.12198

  18. NFKB1 −94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma

    British Journal of Haematology

    Volume 168, Issue 5, March 2015, Pages: 679–688, Gergely Varga, Gábor Mikala, Hajnalka Andrikovics, Magdalena Koszarska, Katalin Balassa, Emma Ádám, András Kozma, Attila Tordai and Tamás Masszi

    Version of Record online : 3 NOV 2014, DOI: 10.1111/bjh.13197

  19. You have free access to this content
    Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma

    American Journal of Hematology

    Volume 87, Issue 12, December 2012, Pages: 1057–1064, Hyun Joo Jung, Zheng Chen and Nami McCarty

    Version of Record online : 11 SEP 2012, DOI: 10.1002/ajh.23317

  20. You have free access to this content
    Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

    Cancer

    Volume 119, Issue 2, 15 January 2013, Pages: 339–347, Darrell White, Adetola Kassim, Birbal Bhaskar, Jing Yi, Karen Wamstad and Virginia E. Paton

    Version of Record online : 18 JUL 2012, DOI: 10.1002/cncr.27745